AstraZeneca PLC Q1 2026 Results

AstraZeneca PLC announced its Q1 2026 financial results, reporting a total revenue of $15,288 million, a 13% increase in actual terms and an 8% increase at constant exchange rates (CER). The company experienced strong revenue growth driven by double-digit increases in Oncology and Rare Disease segments. Key performance indicators include a 12% increase in core operating profit and a 5% increase in core Earnings Per Share (EPS), although the latter reflects a favorable tax rate in the prior year. AstraZeneca confirmed its full-year 2026 guidance, expecting mid-to-high single-digit percentage growth in total revenue and low double-digit percentage growth in core EPS. The company also highlighted positive clinical trial readouts for several high-value New Molecular Entities (NMEs), including tozorakimab and efzimfotase alfa, and secured 14 approvals in major regions since Q4 2025. Significant corporate developments include strategic collaborations with Jacobio Pharma, Pinetree Therapeutics, and CSPC Pharmaceuticals, involving substantial upfront payments and potential milestone achievements. The company also released its third Sustainability Impact Publication, detailing progress on climate action, health equity, and health systems resilience.